pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 29·1 min read
save

Benchmarking Clinical LLMs Proves Complex After Recent Nature Medicine Study

Jul 29, 2026·read at STAT ↗Neutral

The STAT AI Prognosis newsletter, written by health‑tech reporter Brittany Trang, looks at why evaluating new clinical large language models is difficult.

A recent Nature Medicine paper compared specialized systems such as OpenEvidence and UpToDate Expert AI with generic large language models, prompting a strong reaction throughout the clinical AI community.

The article points out that variations in data sources, evaluation metrics, and real‑world usage scenarios make direct comparisons hard, underscoring the need for clearer benchmarking standards.

Investor interest in AI for biopharma is mentioned, but the focus remains on methodological challenges rather than any specific product approval.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicated”

read at STAT ↗
607 words · retrieved Jul 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING
drugs
DisPATCH
topics
ApprovalRecall

related stories

  • Aug 26Vitruvias vanishes amid thyroid tablets recall over potential ‘superpotency’ concernsBioSpace
  • Jun 1The hidden history of BPC-157, a favorite MAHA peptideSTAT
  • Jun 11Summit pulls $500M share sale a day after announcing itBioPharma Dive
  • Jun 11Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testBioPharma Dive
  • Jun 5Tiny HHS office tasked with protecting research participants’ safety is running on fumesSTAT